Sign In
Buy XOMA
$41.70
+0.0100 (+0.0240%)
At Close: Jun 03, 2026
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
04:43pm, Thursday, 02'nd Oct 2025
EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) and LAVA Therapeutics N.V.
ESSA Pharma Inc. Amends Agreement with XenoTherapeutics
06:00am, Wednesday, 24'th Sep 2025
Shareholders expected to receive approximately $0.12 per share in cash upon closing of transaction and up to approximately $0.14 per CVR under revised terms Further Adjourns Special Meeting to October
XOMA Royalty Declares Quarterly Preferred Stock Dividends
07:30am, Monday, 22'nd Sep 2025
EMERYVILLE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Roy
Does XOMA Royalty (XOMA) Have the Potential to Rally 85.34% as Wall Street Analysts Expect?
10:55am, Friday, 19'th Sep 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 85.3% in XOMA Royalty (XOMA). While the effectiveness of this highly sought-after metric is questionable, the p
XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.
09:00am, Wednesday, 17'th Sep 2025
EMERYVILLE, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) (“XOMA Royalty” or the “Company”), a biotechnology royalty aggregator playing a distinctive role
Wall Street Analysts Predict an 86.05% Upside in XOMA Royalty (XOMA): Here's What You Should Know
10:56am, Wednesday, 03'rd Sep 2025
The mean of analysts' price targets for XOMA Royalty (XOMA) points to an 86.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among an
XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference
07:30am, Wednesday, 03'rd Sep 2025
EMERYVILLE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Inve
Here's Why XOMA Royalty (XOMA) Is a Great 'Buy the Bottom' Stock Now
10:56am, Monday, 01'st Sep 2025
After losing some value lately, a hammer chart pattern has been formed for XOMA Royalty (XOMA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate re
WALTHAM, Mass. and DUBLIN and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company (“Mural”), and XOMA Royalty Corporat
WALTHAM, Mass., DUBLIN, Ireland and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company (“Mural”), and XOMA Royalty Co
How Much Upside is Left in XOMA Royalty (XOMA)? Wall Street Analysts Think 106.15%
10:56am, Monday, 18'th Aug 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 106.2% in XOMA Royalty (XOMA). While the effectiveness of this highly sought-after metric is questionable, the
XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates
09:55am, Wednesday, 13'th Aug 2025
XOMA Royalty (XOMA) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of a loss of $0.12 per share. This compares to a loss of $0.28 per share a year ago.
XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
07:30am, Wednesday, 13'th Aug 2025
Business development : Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA Ro
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of H
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of HilleVax, Inc.
06:01pm, Tuesday, 05'th Aug 2025
NEW YORK , Aug. 5, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by HilleVax, Inc. (NASDAQ: HLVX) and its board of directors concerning the proposed acquisi
